Electronic Supplementary Material (ESI) for New Journal of Chemistry. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2018

Supplementary material

Stereoselective synthesis of carbohydrate fused pyrano[3,2c]pyranones as anticancer agents

Priti Kumari^{a†}, Sonal Gupta^{b†}, Chintam Narayana^{a‡}, Shakeel Ahmad^{b‡}, Shailja Singh^{b*} and Ram Sagar^{a,c*}

^aDepartment of Chemistry, Shiv Nadar University, NH-91 Dadri, GB Nagar (UP) 201314, India ^bSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi-110067,India ^cDepartment of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005 India

Corresponding Author:

Email: <u>ram.sagar@snu.edu.in, shailja.jnu@gmail.com</u>, [†]equal contribution [‡]equal contribution

S. No.	Contents	Page No.
1	Synthesis of Compound 1a and 1b	S2
2	Synthesis and NMR data of 4-hydroxycoumarins 1-10	S2-S5
3	Copies of ¹ H NMR and ¹³ C NMR of 4-hydroxycoumarins 1-10	S6-S15
4	Copies of ¹ H NMR and ¹³ C NMR of pyrano[3,2-c]pyranones 11-30a/b	S16-S35
5	Copies of NOE, ${}^{1}H{}^{-1}H$ COSY and ${}^{1}H{}^{-1}C$ HSQC of compound 12	S36-S37
6	HPLC data of compounds 12-14	S38-S40
7	MTT assay for compounds 12-14 in HEK 293cells (Fig. S1)	S41
8	Cellular uptake images of compounds 5 and 12-14 (Fig. S2)	S41

General experimental procedures

Synthesis of 2-C-formyl galactal 1a and 2-C-formyl glucal 1b: In a 100 mL round bottom flask 30 mL anhydrous DMF was added followed by dropwise addition of POCl₃ (0.6 mL, 21.6 mmol) at 0 °C and resulting mixture was stirred for 30 min under Argon atmosphere. A solution (dissolved in anhydrous DMF) of 3,4,6-tri-*O*-benzyl-D-galactal (2.99 g, 7.20 mmol) was added to this dropwise within 30 min. The resulting reaction mixture was stirred at 0 °C to room temperature for 5 h which shows disappearance of starting material (TLC). Reaction mixture was quenched by slow addition of (within 30 min) of chilled NaHCO₃ (30 mL) solution at 0 °C. Mixture was extracted with ethyl acetate (3×30 mL).and combined organic layer washed with brine solution (3×30 mL).then dried over anhydrous Na₂SO₄. The combined organic layer was evaporated under vaccume to get crude residue which was purified though flash column chromatography and pure 2-C-formyl galactal **1a** was isolated in 94% isolated yield (3.0 g). Similarly using 3,4,6-tri-*O*-benzyl-D-galucal and adopting above protocol 2-C-formyl glucal **1b** was obtained in 54% (1.7g) isolated yield [1].

Synthesis of 4-hydroxycoumarins 1-10: In an oven dried 100 mL round bottom flask 2-hydroxyacetophenone (0.4 mL, 3.67 mmol) was suspended in anhydrous toluene (20 mL) at room temperature. The mixture was placed to ice bath at 0 °C and sodium hydride (880 mg, 36.7 mmol) was added to this under Argon atmosphere. The reaction mixture was vigorously stirred for 20 min at same temperature then warm to room temperature. Diethylcarbonate (1.3 mL, 11.01mmol) was added to this and reaction mixture was refluxed (110 °C) for 4h. After completion of reaction (4 h) the reaction mixture was cooled to room temperature then filtered through Buchner funnel under vacuum. The solid residue thus obtained was suspended in ice cold water (50 mL) and acidified by adding 2 N HCl dropwise (pH 1-2). The solid precipitate obtained was filtered through Buchner funnel under vaccum till dryness to get almost pure 4-hydroxycoumarin **1** in 81% yield (482 mg) [2]. Similar reaction protocol was adopted for the synthesis of substituted 4-hydroxycoumarins **2-10** using respective substituted 2-hydroxyacetophenones and results are summarized in table S1

References

^{1.} Ramesh N., Balasubramanian K.K, Tetrahedron Lett. 1991, 32: 3875-3878.

^{2.} Jian W, Haibing G, Saofa S, Jiayao H, Lei W, Shiyong P, *Adv.Synth.Catal*.2013, 355:2550-2557.

Table S1.Synthesis of 4-hydroxy coumarins 1-10.

	R ² R ³	R ¹ O OH R ⁴	C + C₂H₅O	OC₂H₅	<u>NaH,Toluene</u> 110°C,4 - 24 h	R^{1} O R^{2} R^{3} O R^{4}	
Entry	R ¹	R ²	R ³	R ⁴	Product	1-10 Time (h)	Yield (%)
1	Н	Н	Н	Н	1	4	81
2	Н	OCH ₃	Н	Н	2	4	68
3	Н	Cl	Н	Н	3	4	68
4	Н	CH_3	Н	Η	4	4	92
5	Н	Br	Н	Η	5	4	81
6	Н	$-C_{6}H_{4}-$		Η	6	4	55
7	Н	Н	F	Н	7	5	85
8	Н	Cl	Н	Cl	8	24	50
9	Η	Н	OCH ₃	OCH ₃	9	5	56
10	OCH ₃	Н	OCH ₃	Н	10	5	94



4-hydroxy-2H-benzopyran-2-one (1). ¹H NMR (400 MHz, DMSO-*d*6): δ 12.53 (brs,1H,OH), 7.82 (dd, J = 1.6 Hz, 8Hz,1H, H-7), 7.66-7.62 (m, 1H, H-6), 7.36 (dd, J = 8.0 Hz,7.2 Hz, 1H, H-7), 5.60 (s, 1H, H-3), ¹³C NMR (100 MHz, DMSO-*d*6): δ 166.0, 162.3, 153.9, 133.1, 124.3, 123.6, 116.8, 116.2, 91.4, HRMS(ESI), calcd, m/z C₉H₆O₃, [M+H]⁺163.0389;Found: 163.0420.



4-hydroxy-6-methoxy-2H-benzopyran-2-one (**2**). ¹H NMR (400 MHz, DMSO-*d6*): δ 12.52 (brs, 1H, OH), 7.30 (dd, J = 4.0 Hz, J = 8.0 Hz, 1H, H-7), 7.22-7.19 (m, 2H, ArH), 5.59 (s, 1H, H-3), 3.80 (s, 1H, OCH₃), ¹³C NMR (100 MHz, DMSO-*d6*): δ 165.8, 162.5, 155.7, 148.3, 120.7, 118.0, 116.6, 105.4, 91.6, 56.0 (OCH₃), HRMS(ESI), calcd, m/z C₁₀H₈O₄, [M+H]⁺ 193.0495; Found: 193.0513.



6-Chloro-4-hydroxy-2H-benzopyran-2-one (3) ¹H NMR (400 MHz, DMSO-*d*6): δ 7.89 (d, *J* = 2.4 Hz, 1H, H-5), 7.79 (dd, *J* = 2.4 Hz and *J* = 8.8 Hz, 1H, H-8), 7.35 (d, *J* = 8.8 Hz, 1H, H-7), 5.62 (s, 1H, H-3), ¹³C NMR (100 MHz, DMSO-*d*6): δ 164.8, 161.8, 152.9, 135.6, 125.7, 119.2, 118.2, 116.1, 92.1, HRMS(ESI), calcd, m/z C₉H₅ClO₃, [M+H]⁺ 196.9999; Found: 197.0014.



4-hydroxy-6 methyl-2H-benzopyran-2-one (4) (400 MHz, DMSO-d6): δ 7.59 (s, 1H, H-5), 7.43 (dd, J = 1.6 Hz and J = 8 Hz), 7.24 (d, J = 8.4 Hz, 1H, H-7), 5.56 (s, 1H), 2.35 (s, 3H, CH₃), ¹³C NMR (100 MHz, DMSO-d6): δ 166.1, 162.5, 152.1, 133.9, 133.5, 123.2, 116.5, 115.9, 91.3, 20.7 (CH₃), HRMS(ESI), calcd, m/z C₁₀H₈O₃, [M+H]⁺ 177.0546; Found: 177.0563.



6-bromo-4-hydroxy-2H-benzopyran-2-one(5) ¹H NMR (400 MHz, DMSO-*d6*): δ 7.90.(d, J = 2 Hz, 1H, H-5), 7.79 (dd, J = 2.0 Hz and J = 7.2 Hz, 1H, H-7), 7.35 (d, J = 7.2 Hz, 1H, H-8), 5.58 (s, 1H, H-3), ¹³C NMR (100 MHz, DMSO-*d6*): δ 164.9, 161.7, 152.6, 132.8, 128.4, 122.8, 118.9, 117.7, 92.1, HRMS(ESI), calcd, m/z C₉H₅BrO₃, [M+H]⁺ 240.9495;Found: 240.9509.



4-hydroxy-2H-benzo[g]benzopyran-2-one (**6**). ¹H NMR (400 MHz, DMSO-*d6*): δ 12.68 (brs, 1H, OH), 8.36-8.33 (m, 1H), 8.05 - 8.02 (m, 1H), 7.82 (s, 2H), 7.73-7.70 (m, 2H), 5.71 (s, 1H, H-3), ¹³C NMR (100 MHz, DMSO-*d6*): δ 167.0, 162.2, 151.1, 135.2, 129.2, 128.5, 127.7, 124.0, 122.6, 122.1, 119.4, 111.5, 91.1 HRMS(ESI), calcd, m/z C₁₃H₈O₃, [M+H]⁺ 213.0546; Found: 213.0567.



7-*flouro-4-hydroxy-2H-benzopyran-2-one* (7) ¹H NMR (400 MHz, DMSO-*d*6): δ 7.85 (dd, J = 6.4 Hz, J = 8.8 Hz, H-7), 7.33 (dd, J = 2.4 Hz and J = 10.0 Hz, H-5), 7.21 (td, J = 2.4 Hz and J = 11.2 Hz, H-6), 5.55 (s, 1H, H-3), ¹³C NMR, (100 MHz, DMSO-*d*6): δ 165.8, 162.2, 155.3, 155.1, 125.9, 125.8, 113.2, 112.3, 112.1, 104.4, 104.1, 90.4, HRMS(ESI), calcd, m/z C₉H₅FO₃, [M+H]⁺ 180.0223;Found: 181.0304.



6, 8-dichloro-4-hydroxy-2H-benzopyran-2-one (8). ¹H NMR (400 MHz, DMSO-d6): δ 7.95 (d, J = 2.4 Hz, 1H, H-8), 7.73(d, J = 2.4 Hz, 1H, H-5), 5.58 (s, 1H, H-3), ¹³C NMR (100 MHz, DMSO-d6): δ 165.4, 160.9, 148.6, 132.2, 128.2, 122.1, 121.7, 119.5, 91.9, HRMS(ESI), calcd, m/z C₉H₄Cl₂O₃, [M+H]⁺ 230.9610; Found: 230.9625.



4-hydroxy-7,8-dimethoxy-2H-benzopyran-2-one (9). ¹H NMR (400 MHz, DMSO-*d6*): δ 7.53 (d, J = 8.8 Hz, 1H, H-5), 7.08 (d, J = 9.2 Hz, 1H, H-6), 5.45 (s, 1H, H-3), 3.89 (s, 1H, OCH₃), 3.79 (s, 1H, OCH₃), ¹³C NMR (100 MHz, DMSO-*d6*): δ 166.4, 162.3, 156.0, 148.0, 135.7, 118.7, 110.5, 109.0, 89.1, 61.1 (OCH₃), 56.7 (OCH₃), HRMS(ESI), calcd, m/z C₁₁H₁₀O₅, [M+H]⁺ 223.0601;Found: 223.0611.



4-hdroxy-5,7-dimethoxy-2H-benzopyran-2-one (10). ¹H NMR (400 MHz, DMSO-*d6*): δ 11.14 (s, 1H, OH), 6.56 (d, J = 2.4 Hz, 1H, H-6), 6.48 (d, J = 2 Hz, 1H, H-8), 5.33 (s, 1H, H-3), 3.86 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), ¹³C NMR (100 MHz, DMSO-*d6*): δ 168.0, 163.7, 162.1, 158.8, 157.4, 95.8, 94.0, 88.6, 56.9, 56.4 (OCH₃), HRMS(ESI), calcd, m/z C₁₁H₁₀O₅, [M+H]⁺ 223.0601; Found: 223.0611.























Aug01-2017 PK-136



















May10-2017 PK-157







$\begin{array}{c} -7.691\\ -7.691\\ -7.337\\ -7.337\\ -7.337\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.277\\ -6.2337\\ -6.277\\ -6.2337\\ -6.277\\ -6.2337\\ -6.2337\\ -6.2337\\ -6.2332\\ -6.2337\\ -6.2332\\ -6.2337\\ -6.2332\\ -6.2337\\ -6.2332\\ -6.232\\ -6.232$





















Peak Summary with Statistics

Name:

	Sample Name	Vial	Inj	Retention Time (min)	Area	% Area	Height
1	pk-12	28	1	9.453	4632759	97.35	676652
2	pk-12	28	1	8.899	125962	2.65	40885
Mean				9.176			
Std. Dev.				0.392			
% RSD				4.27			



	Sample Name	Vial	Inj	Retention Time (min)	Area	% Area	Height
1	PK-13	29	1	8.863	30908	0.89	7275
2	PK-13	29	1	10.735	3422118	98.44	828679
3	PK-13	29	1	9.480	23164	0.67	8187
Mean				9.693			
Std. Dev.				0.954			
% RSD				9.84			

HPLC data of 14



Peak Summary with Statistics

Name:

	Sample Name	Vial	Inj	Retention Time (min)	Area	% Area	Height
1	PK-14	30	1	10.571	10599283	99.02	2484772
2	PK-14	30	1	9.484	104385	0.98	32554
Mean				10.028			
Std. Dev.				0.768			
% RSD				7.66			



Fig S1. Growth inhibition assay for compound 12, 13 and 14 against in HEK 293cells.



Fig. S2. Cellular uptake of Galactal fused pyrano-pyranones 12, 13 and 14. MCF 7 cells were grown on coverslips and treated with compounds for different time points as shown. Fluorescence microscopic images showed increase uptake and intracellular accumulation (arrows) of these compounds by cancer cells as compared to parent compound 5. Scale bar = 10 μ m.